RU2001104890A - Compounds of N, N-substituted cyclic amine - Google Patents
Compounds of N, N-substituted cyclic amineInfo
- Publication number
- RU2001104890A RU2001104890A RU2001104890/04A RU2001104890A RU2001104890A RU 2001104890 A RU2001104890 A RU 2001104890A RU 2001104890/04 A RU2001104890/04 A RU 2001104890/04A RU 2001104890 A RU2001104890 A RU 2001104890A RU 2001104890 A RU2001104890 A RU 2001104890A
- Authority
- RU
- Russia
- Prior art keywords
- cyano
- piperazine
- methyl
- ethyl
- hexyl
- Prior art date
Links
- -1 cyclic amine Chemical class 0.000 title claims 12
- 229910052757 nitrogen Inorganic materials 0.000 title claims 10
- 150000001875 compounds Chemical class 0.000 title claims 8
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 80
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 36
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 19
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 14
- 239000011780 sodium chloride Substances 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 7
- 239000004480 active ingredient Substances 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 230000002490 cerebral Effects 0.000 claims 4
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 210000002569 neurons Anatomy 0.000 claims 4
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 239000000480 calcium channel blocker Substances 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- DHJTVHWWCBYQHX-UHFFFAOYSA-N 2-(4-aminophenyl)-5-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-propan-2-ylpentanenitrile Chemical compound C=1C=C(N)C=CC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 DHJTVHWWCBYQHX-UHFFFAOYSA-N 0.000 claims 2
- UIQJKAOWKGMXDU-UHFFFAOYSA-N 2-(4-chlorophenyl)-5-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-propan-2-ylpentanenitrile Chemical compound C=1C=C(Cl)C=CC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 UIQJKAOWKGMXDU-UHFFFAOYSA-N 0.000 claims 2
- PQQYVTPNFNYRIX-UHFFFAOYSA-N 2-[4-(dimethylamino)phenyl]-5-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-propan-2-ylpentanenitrile Chemical compound C=1C=C(N(C)C)C=CC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 PQQYVTPNFNYRIX-UHFFFAOYSA-N 0.000 claims 2
- WOOAWDMJKDSJHW-UHFFFAOYSA-N 4-[3-cyano-6-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-methylhexan-3-yl]benzonitrile Chemical compound C=1C=C(C#N)C=CC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 WOOAWDMJKDSJHW-UHFFFAOYSA-N 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 2
- GVDUKPVDFXGFEM-UHFFFAOYSA-N 5-[3-cyano-6-[4-[2-(3-fluorophenoxy)ethyl]piperazin-1-yl]-2-methylhexan-3-yl]thiophene-2-carbonitrile Chemical compound C=1C=C(C#N)SC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=CC(F)=C1 GVDUKPVDFXGFEM-UHFFFAOYSA-N 0.000 claims 2
- UZNNCHDSFCJLGM-UHFFFAOYSA-N 5-[3-cyano-6-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-methylhexan-3-yl]thiophene-2-carbonitrile Chemical compound C=1C=C(C#N)SC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 UZNNCHDSFCJLGM-UHFFFAOYSA-N 0.000 claims 2
- XCLNZZVJSMBOIO-UHFFFAOYSA-N 5-[4-[2-(3-fluorophenoxy)ethyl]piperazin-1-yl]-2-propan-2-yl-2-thiophen-2-ylpentanenitrile Chemical compound C=1C=CSC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=CC(F)=C1 XCLNZZVJSMBOIO-UHFFFAOYSA-N 0.000 claims 2
- KBIXFTAOQKIMDT-UHFFFAOYSA-N 5-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-(2-fluorophenyl)-2-propan-2-ylpentanenitrile Chemical compound C=1C=CC=C(F)C=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 KBIXFTAOQKIMDT-UHFFFAOYSA-N 0.000 claims 2
- SCJOCYBVGISVMJ-UHFFFAOYSA-N 5-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-(3-fluorophenyl)-2-propan-2-ylpentanenitrile Chemical compound C=1C=CC(F)=CC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 SCJOCYBVGISVMJ-UHFFFAOYSA-N 0.000 claims 2
- WRDPQUAUJUTPAV-UHFFFAOYSA-N 5-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-(4-fluorophenyl)-2-propan-2-ylpentanenitrile Chemical compound C=1C=C(F)C=CC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 WRDPQUAUJUTPAV-UHFFFAOYSA-N 0.000 claims 2
- PLYLOSAVRCVWEB-UHFFFAOYSA-N 5-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-(4-hydroxyphenyl)-2-propan-2-ylpentanenitrile Chemical compound C=1C=C(O)C=CC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 PLYLOSAVRCVWEB-UHFFFAOYSA-N 0.000 claims 2
- UYTBUPXGZVMBLS-UHFFFAOYSA-N 5-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-(4-methoxyphenyl)-2-propan-2-ylpentanenitrile Chemical compound C1=CC(OC)=CC=C1C(C(C)C)(C#N)CCCN1CCN(CCOC=2C=CC(F)=CC=2)CC1 UYTBUPXGZVMBLS-UHFFFAOYSA-N 0.000 claims 2
- GHLGHYQRBBNGSF-UHFFFAOYSA-N 5-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-(4-methylphenyl)-2-propan-2-ylpentanenitrile Chemical compound C=1C=C(C)C=CC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 GHLGHYQRBBNGSF-UHFFFAOYSA-N 0.000 claims 2
- BSHDIVLDMVFZLQ-UHFFFAOYSA-N 5-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-(4-nitrophenyl)-2-propan-2-ylpentanenitrile Chemical compound C=1C=C([N+]([O-])=O)C=CC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 BSHDIVLDMVFZLQ-UHFFFAOYSA-N 0.000 claims 2
- ZKFHLUBCPSGLQC-UHFFFAOYSA-N 5-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-[4-(hydroxyiminomethyl)phenyl]-2-propan-2-ylpentanenitrile Chemical compound C=1C=C(C=NO)C=CC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 ZKFHLUBCPSGLQC-UHFFFAOYSA-N 0.000 claims 2
- SBHVPAXDVAOADX-UHFFFAOYSA-N 5-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-[4-(hydroxymethyl)phenyl]-2-propan-2-ylpentanenitrile Chemical compound C=1C=C(CO)C=CC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 SBHVPAXDVAOADX-UHFFFAOYSA-N 0.000 claims 2
- GGVOXCWQQDMJRQ-UHFFFAOYSA-N 5-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-propan-2-yl-2-pyridin-3-ylpentanenitrile Chemical compound C=1C=CN=CC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 GGVOXCWQQDMJRQ-UHFFFAOYSA-N 0.000 claims 2
- HQPZVORBNFWTMK-UHFFFAOYSA-N 5-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-propan-2-yl-2-thiophen-2-ylpentanenitrile Chemical compound C=1C=CSC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 HQPZVORBNFWTMK-UHFFFAOYSA-N 0.000 claims 2
- 206010002855 Anxiety Diseases 0.000 claims 2
- 206010057666 Anxiety disease Diseases 0.000 claims 2
- YKNXRJYMPRRKHC-UHFFFAOYSA-N N-[4-[3-cyano-6-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-methylhexan-3-yl]phenyl]acetamide Chemical compound C=1C=C(NC(C)=O)C=CC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 YKNXRJYMPRRKHC-UHFFFAOYSA-N 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 125000004429 atoms Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000001771 impaired Effects 0.000 claims 2
- WJZVFBAPUDAHLN-UHFFFAOYSA-N methyl 4-[3-cyano-6-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-methylhexan-3-yl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(C(C)C)(C#N)CCCN1CCN(CCOC=2C=CC(F)=CC=2)CC1 WJZVFBAPUDAHLN-UHFFFAOYSA-N 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 210000003867 nerve cell Anatomy 0.000 claims 2
- 125000004430 oxygen atoms Chemical group O* 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004434 sulfur atoms Chemical group 0.000 claims 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010004939 Bipolar I disease Diseases 0.000 claims 1
- 206010004938 Bipolar disease Diseases 0.000 claims 1
- 210000004556 Brain Anatomy 0.000 claims 1
- 108090000312 Calcium Channels Proteins 0.000 claims 1
- 102000003922 Calcium Channels Human genes 0.000 claims 1
- 206010008118 Cerebral infarction Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010008190 Cerebrovascular accident Diseases 0.000 claims 1
- 208000008208 Craniocerebral Trauma Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000001636 Diabetic Neuropathy Diseases 0.000 claims 1
- 206010012680 Diabetic neuropathy Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 206010061256 Ischaemic stroke Diseases 0.000 claims 1
- 230000036740 Metabolism Effects 0.000 claims 1
- 206010027599 Migraine Diseases 0.000 claims 1
- 208000008085 Migraine Disorders Diseases 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 108010075750 P-Type Calcium Channels Proteins 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 108010027023 Q-Type Calcium Channels Proteins 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 125000002723 alicyclic group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000005085 alkoxycarbonylalkoxy group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 201000006474 brain ischemia Diseases 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000006038 hexenyl group Chemical group 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 230000035786 metabolism Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000005936 piperidyl group Chemical group 0.000 claims 1
- 230000000069 prophylaxis Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 125000004001 thioalkyl group Chemical group 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
Claims (15)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10/205709 | 1998-07-21 | ||
JP20570998 | 1998-07-21 | ||
JP10/280103 | 1998-10-01 | ||
JP28010398 | 1998-10-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2001104890A true RU2001104890A (en) | 2003-09-27 |
RU2232156C2 RU2232156C2 (en) | 2004-07-10 |
Family
ID=26515211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2001104890/04A RU2232156C2 (en) | 1998-07-21 | 1999-07-21 | Compounds of n,n-substituted cyclic amine |
Country Status (14)
Country | Link |
---|---|
US (1) | US6737425B1 (en) |
EP (1) | EP1099692B1 (en) |
KR (1) | KR100627608B1 (en) |
CN (1) | CN1310709A (en) |
AT (1) | ATE325097T1 (en) |
AU (1) | AU758246B2 (en) |
CA (1) | CA2337941A1 (en) |
DE (1) | DE69931163T2 (en) |
HU (1) | HUP0103530A3 (en) |
NO (1) | NO318797B1 (en) |
NZ (1) | NZ509310A (en) |
RU (1) | RU2232156C2 (en) |
TW (1) | TWI250152B (en) |
WO (1) | WO2000005210A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6667412B1 (en) | 1999-03-16 | 2003-12-23 | Eisai Co., Ltd. | Nitrile compound |
NZ519981A (en) * | 2000-01-20 | 2005-02-25 | Eisai Co Ltd | Nitrogenous cyclic compounds and pharmaceutical compositions containing the same |
WO2001066534A2 (en) * | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
JP4428053B2 (en) | 2002-02-05 | 2010-03-10 | 味の素株式会社 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist |
EP1943222A1 (en) * | 2005-10-13 | 2008-07-16 | Morphochem Aktiengesellschaft Für Kombinatorische Chemie | Antibacterial active 5-chinolin derivative |
KR101038053B1 (en) * | 2008-08-06 | 2011-05-31 | 임봉근 | Structure of sandals sole |
CN102199122A (en) * | 2010-03-23 | 2011-09-28 | 范扶民 | Homopiperazine derivative and preparation method thereof |
WO2015200674A1 (en) * | 2014-06-25 | 2015-12-30 | The General Hospital Corporation | Neuroactive compounds and methods of using the same |
GB2536650A (en) | 2015-03-24 | 2016-09-28 | Augmedics Ltd | Method and system for combining video-based and optic-based augmented reality in a near eye display |
MD3483164T2 (en) | 2017-03-20 | 2020-07-31 | Forma Therapeutics Inc | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators |
WO2019211741A1 (en) | 2018-05-02 | 2019-11-07 | Augmedics Ltd. | Registration of a fiducial marker for an augmented reality system |
WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
US11766296B2 (en) | 2018-11-26 | 2023-09-26 | Augmedics Ltd. | Tracking system for image-guided surgery |
US11980506B2 (en) | 2019-07-29 | 2024-05-14 | Augmedics Ltd. | Fiducial marker |
US11382712B2 (en) | 2019-12-22 | 2022-07-12 | Augmedics Ltd. | Mirroring in image guided surgery |
US11896445B2 (en) | 2021-07-07 | 2024-02-13 | Augmedics Ltd. | Iliac pin and adapter |
CN114315802B (en) * | 2021-12-14 | 2023-06-16 | 西安医学院 | Quinazoline nitrogen-containing heterocyclic derivative, preparation method and application |
WO2024057210A1 (en) | 2022-09-13 | 2024-03-21 | Augmedics Ltd. | Augmented reality eyewear for image-guided medical intervention |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1670478A1 (en) | 1967-10-12 | 1971-02-11 | Cassella Farbwerke Mainkur Ag | Process for the preparation of derivatives of alpha-piperazino-phenylacetonitrile |
SE8500573D0 (en) | 1985-02-08 | 1985-02-08 | Ferrosan Ab | NOVEL PIPERAZINECARBOXAMIDES HAVING A PHENOXYALKYL OR THIOPHENOXYALKYL SIDE CHAIN |
ES2053480T3 (en) * | 1986-07-31 | 1994-08-01 | Otsuka Pharma Co Ltd | A PROCEDURE FOR PREPARING A CARBOESTIRILE DERIVATIVE. |
JPH0283375A (en) * | 1988-09-21 | 1990-03-23 | Dainippon Pharmaceut Co Ltd | 2-substituted piperazinyl-2-(1,2-benzisoxazol-3-yl)acetic acid derivative |
WO1990013539A1 (en) | 1989-04-28 | 1990-11-15 | Meiji Seika Kaisha, Ltd. | New n-substituted piperazine derivatives and drug for improving functional disorder of brain |
EP0441226A1 (en) | 1990-01-29 | 1991-08-14 | J. URIACH & CIA. S.A. | (cyanomethyl)pyridines useful as PAF antagonists |
ES2036926B1 (en) | 1991-08-08 | 1994-01-16 | Uriach & Cia Sa J | "PROCEDURE FOR THE OBTAINING OF DERIVATIVES OF (2-ALKYL-3-PIRIDIL) METHYLPIPERAZINE". |
JPH0597673A (en) | 1991-10-08 | 1993-04-20 | Ajinomoto Co Inc | Antiarrhythmic agent |
ES2062943B1 (en) | 1993-03-23 | 1995-11-16 | Uriach & Cia Sa J | NEW DERIVATIVES OF (2-METHYL-3-PIRIDIL) CYANOMETILPIPERAZINES. |
CA2204082A1 (en) | 1996-05-03 | 1997-11-03 | Michael William John Urquhart | Pharmaceutical compounds |
US6667412B1 (en) | 1999-03-16 | 2003-12-23 | Eisai Co., Ltd. | Nitrile compound |
-
1999
- 1999-07-20 TW TW088112295A patent/TWI250152B/en not_active IP Right Cessation
- 1999-07-21 WO PCT/JP1999/003900 patent/WO2000005210A1/en active IP Right Grant
- 1999-07-21 AT AT99931461T patent/ATE325097T1/en not_active IP Right Cessation
- 1999-07-21 KR KR1020017000901A patent/KR100627608B1/en not_active IP Right Cessation
- 1999-07-21 US US09/743,358 patent/US6737425B1/en not_active Expired - Fee Related
- 1999-07-21 EP EP99931461A patent/EP1099692B1/en not_active Expired - Lifetime
- 1999-07-21 CN CN99808878A patent/CN1310709A/en active Pending
- 1999-07-21 AU AU47980/99A patent/AU758246B2/en not_active Ceased
- 1999-07-21 CA CA002337941A patent/CA2337941A1/en not_active Abandoned
- 1999-07-21 NZ NZ509310A patent/NZ509310A/en unknown
- 1999-07-21 DE DE69931163T patent/DE69931163T2/en not_active Expired - Lifetime
- 1999-07-21 RU RU2001104890/04A patent/RU2232156C2/en not_active IP Right Cessation
- 1999-07-21 HU HU0103530A patent/HUP0103530A3/en unknown
-
2001
- 2001-01-18 NO NO20010303A patent/NO318797B1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2001104890A (en) | Compounds of N, N-substituted cyclic amine | |
ES2871027T3 (en) | Strong soluble epoxy hydrolase inhibitors | |
DE60222248T2 (en) | AMINOMETHYL GROUPS CONTAINING N- (ARYLSULFONYL) BETA AMINOIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND THEIR PHARMACEUTICAL PREPARATIONS | |
KR101308527B1 (en) | Treatment of parkinsons's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands | |
ES2216266T3 (en) | 1-FENIL-4-BENCILPIPERAZINAS: SPECIFIC LINKS OF THE DOPAMINE RECEPTOR SUBTIPE D4. | |
US20020183335A1 (en) | 2, 4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulators | |
RU2002101935A (en) | Amine and amide derivatives as ligands for the neuropeptide Y receptor Y5 used to treat obesity and other disorders | |
RU96104356A (en) | AMIDIN DERIVATIVES WITH ACTIVITY AGAINST NITROGEN OXIDE SYNTHETASIS (U) | |
RU2003128992A (en) | OMEGA AMINOalkylamides of R-2-arylpropionic acids as inhibitors of chemotaxis of polymorphic and mononuclear cells | |
CA2396590A1 (en) | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | |
RU2004130426A (en) | CYCLIC AMIDES | |
NZ603724A (en) | Piperidine derivatives and their use for the treatment of metabolic disorders | |
JP2003507328A5 (en) | ||
KR970061872A (en) | Phenolic Compounds and Methods for Making the Same | |
RU2002122095A (en) | NEW PIPYRIDINE COMPOUND AND ITS PHARMACEUTICAL COMPOSITION | |
CA2722776A1 (en) | Nmda receptor antagonists for the treatment of neuropsychiatric disorders | |
WO2005056524A3 (en) | Therapeutic agents useful for treating pain | |
CA2446326A1 (en) | 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | |
RU2005119627A (en) | PHOSPHODESTHESIS INHIBITORS 4 | |
RU2004126936A (en) | QUINOLINE DERIVATIVES AS NPV ANTAGONISTS | |
RU2007101522A (en) | DIARYLMETHYL PIPERAZINE DERIVATIVES, THEIR PRODUCTION AND USE | |
CA2420568A1 (en) | Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases | |
RU2004107854A (en) | 4 [PIPERIDIN-4-YLIDEN- (3-CARBOMOILYPHENYL) METHYL] BENZAMIDE DERIVATIVES AND THEIR APPLICATION FOR TREATMENT OF PAIN, SPINAL DAMAGE OR GASTROINTESTINAL DISORDERS | |
ATE403426T1 (en) | OPIOID RECEPTOR ACTIVE 4-(3-HYDROXYPHENYL) OR 4-(3-ALKOXYPHENYL)-1,2,4-TRIAZOLE COMPOUNDS | |
US4956363A (en) | Treatment of cognitive and behavioral disorders associated with aging and with dementia syndromes |